Skip to main content
Journal cover image

p53 overexpression in advanced-stage endometrial adenocarcinoma.

Publication ,  Journal Article
Kohler, MF; Carney, P; Dodge, R; Soper, JT; Clarke-Pearson, DL; Marks, JR; Berchuck, A
Published in: Am J Obstet Gynecol
November 1996

OBJECTIVES: Mutation and overexpression of the p53 tumor suppressor gene in endometrial cancers are associated with advanced stage and poor survival. We sought to determine whether p53 overexpression is an independent variable predictive of poor prognosis in advanced endometrial adenocarcinomas. STUDY DESIGN: Immunohistochemical evaluation was used to examine p53 expression in paraffin blocks from 179 endometrial adenocarcinomas. RESULTS: p53 overexpression was seen in 35% of cancers and was associated with higher stage (p = 0.004), black race (p < 0.001), higher grade (p = 0.02), lack of hormone replacement (p = 0.04), and older age (p = 0.05). In addition to a higher frequency of p53 overexpression (57% vs 26%), black women had a lower survival rate than white women (p = 0.001), but overexpression was associated with poor survival in both races. After we corrected for hormone use, multivariate analysis revealed that older age (p < 0.001), higher stage (p < 0.001), higher grade (p = 0.01), and p53 overexpression (p = 0.04) were predictive of poor survival. CONCLUSIONS: Overexpression of p53 in advanced-stage endometrial cancers is an independent variable that is associated with poor survival, occurs more frequently in black women, and may contribute to the racial disparity in survival.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Obstet Gynecol

DOI

ISSN

0002-9378

Publication Date

November 1996

Volume

175

Issue

5

Start / End Page

1246 / 1252

Location

United States

Related Subject Headings

  • Prognosis
  • Peptide Elongation Factor Tu
  • Obstetrics & Reproductive Medicine
  • Neoplasm Staging
  • Mitochondrial Proteins
  • Middle Aged
  • Immunohistochemistry
  • Humans
  • Female
  • Endometrial Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kohler, M. F., Carney, P., Dodge, R., Soper, J. T., Clarke-Pearson, D. L., Marks, J. R., & Berchuck, A. (1996). p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol, 175(5), 1246–1252. https://doi.org/10.1016/s0002-9378(96)70036-4
Kohler, M. F., P. Carney, R. Dodge, J. T. Soper, D. L. Clarke-Pearson, J. R. Marks, and A. Berchuck. “p53 overexpression in advanced-stage endometrial adenocarcinoma.Am J Obstet Gynecol 175, no. 5 (November 1996): 1246–52. https://doi.org/10.1016/s0002-9378(96)70036-4.
Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL, Marks JR, et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol. 1996 Nov;175(5):1246–52.
Kohler, M. F., et al. “p53 overexpression in advanced-stage endometrial adenocarcinoma.Am J Obstet Gynecol, vol. 175, no. 5, Nov. 1996, pp. 1246–52. Pubmed, doi:10.1016/s0002-9378(96)70036-4.
Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL, Marks JR, Berchuck A. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol. 1996 Nov;175(5):1246–1252.
Journal cover image

Published In

Am J Obstet Gynecol

DOI

ISSN

0002-9378

Publication Date

November 1996

Volume

175

Issue

5

Start / End Page

1246 / 1252

Location

United States

Related Subject Headings

  • Prognosis
  • Peptide Elongation Factor Tu
  • Obstetrics & Reproductive Medicine
  • Neoplasm Staging
  • Mitochondrial Proteins
  • Middle Aged
  • Immunohistochemistry
  • Humans
  • Female
  • Endometrial Neoplasms